Catalent Inc (NYSE:CTLT)
$ 58.48 -0.21 (-0.36%) Market Cap: 10.61 Bil Enterprise Value: 15.28 Bil PE Ratio: 0 PB Ratio: 2.94 GF Score: 79/100

Catalent Inc to Acquire Gene Therapy Leader Paragon Bioservices Inc - M&A Call Transcript

Apr 15, 2019 / 12:30PM GMT
Release Date Price: $44.41 (+13.12%)
Operator

Good morning, ladies and gentlemen, and welcome to the Catalent Investor Call. (Operator Instructions) As a reminder, this call may be recorded.

I would now like to introduce your host for today's conference, Mr. Thomas Castellano, Vice President Investor Relation, Treasurer. You may begin.

Thomas Castellano
Catalent, Inc. - VP of Finance & IR and Treasurer

Thank you, operator. Good morning, everyone, and thank you for joining us today to discuss Catalent's agreement to acquire Paragon Bioservices, which we announced earlier today.

Joining me today is John Chiminski, Chairman and Chief Executive Officer of Catalent will take us through our prepared remarks; and Wetteny Joseph, Chief Financial Officer.

You'll find a brief slide presentation in the Investor's section of our website catalent.com, and we'll walk you through that deck this morning.

Before we begin, I'd like to draw your attention to the forward-looking statements and additional legal information, which are available at the beginning of the presentation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot